Hydroxyzine and Prevymis drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Hydroxyzine (hydroxyzine hydrochloride) and Prevymis (letermovir). Common drug interactions include herpes zoster among females and febrile neutropenia among males.

The phase IV clinical study analyzes what interactions people have when they take Hydroxyzine and Prevymis. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Hydroxyzine?

Hydroxyzine has active ingredients of hydroxyzine hydrochloride. It is often used in stress and anxiety. eHealthMe is studying from 54,069 Hydroxyzine users. Check the latest studies of Hydroxyzine.

What is Prevymis?

Prevymis has active ingredients of letermovir. eHealthMe is studying from 1,328 Prevymis users. Check the latest studies of Prevymis.



On Jul, 15, 2026

14 people who take Hydroxyzine and Prevymis together, and have interactions are studied.

Hydroxyzine and Prevymis drug interactions.

What are the common drug interactions of Hydroxyzine and Prevymis, by gender? *:

female:

  1. Herpes zoster
  2. Pericardial effusion (fluid around the heart)

male:

  1. Febrile neutropenia (fever with reduced white blood cells)
  2. Platelet count decreased
  3. Immune system disorder
  4. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  5. Post inflammatory pigmentation change
  6. Superinfection fungal
  7. Telangiectasia (small dilated blood vessels near the surface of the skin)
  8. Pneumonia
  9. Engraftment syndrome (inflammatory condition during neutrophil recovery after hematopoietic stem cell transplantation)
  10. Venoocclusive liver disease (small veins in the liver are obstructed)

What are the common drug interactions of Hydroxyzine and Prevymis, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Venoocclusive liver disease (small veins in the liver are obstructed)
  2. Coma hepatic (accumulation in the bloodstream of toxic substances that are normally removed by the liver leads coma)
  3. Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)
  4. Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
  5. Hepatic failure (liver failure)
  6. Immune system disorder
  7. Pericardial effusion (fluid around the heart)
  8. Engraftment syndrome (inflammatory condition during neutrophil recovery after hematopoietic stem cell transplantation)
  9. Platelet count decreased

20-29:

n/a

30-39:

n/a

40-49:

  1. Febrile neutropenia (fever with reduced white blood cells)
  2. Pneumonia
  3. Graft versus host disease in skin (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the skin)
  4. Post inflammatory pigmentation change
  5. Superinfection fungal
  6. Telangiectasia (small dilated blood vessels near the surface of the skin)

50-59:

  1. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  2. Platelet count decreased

60+:

n/a

What are the existing conditions these people have? *

  1. Stomatitis (inflammation of mucous membrane of mouth): 8 people, 57.14%
  2. Nausea (feeling of having an urge to vomit): 6 people, 42.86%
  3. Oedema (fluid collection in tissue): 6 people, 42.86%
  4. Thrombocytopenia (decrease of platelets in blood): 6 people, 42.86%
  5. Hypokalemia (low potassium): 6 people, 42.86%
  6. Psoriasis (immune-mediated disease that affects the skin): 6 people, 42.86%
  7. Irritable Bowel Syndrome: 6 people, 42.86%
  8. Obsessive-Compulsive Disorder (an anxiety disorder characterized by intrusive thoughts that produce uneasiness, apprehension, fear, or worry;): 6 people, 42.86%
  9. Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood): 5 people, 35.71%
  10. Febrile Neutropenia (fever with reduced white blood cells): 5 people, 35.71%

* Approximation only. Some reports may have incomplete information.

Do you take Hydroxyzine and Prevymis?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Hydroxyzine and Prevymis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Hydroxyzine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Prevymis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Hydroxyzine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Prevymis and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on hydroxyzine hydrochloride and letermovir (the active ingredients of Hydroxyzine and Prevymis, respectively), and Hydroxyzine and Prevymis (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: